Physician profile
John Warren
NPI 1386634400
$4,311.37
in general payments reported to CMS, 2019-2025
22 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $295 · 2021: $366 · 2022: $341 · 2023: $675 · 2024: $1,237 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,740.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $714.34 | 2023-2024 | Iheezo |
| Alcon Vision LLC | $693.28 | 2019-2025 | Clareon, Hydrus Microstent, Wavelight Refractive Suite |
| Glaukos Corporation | $493.14 | 2024-2025 | Idosetr, Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Abbvie INC. | $291.07 | 2023-2025 | Durysta |
| Mallinckrodt Hospital Products INC. | $269.66 | 2021-2024 | Acthar |
| Ocular Therapeutix, INC. | $253.89 | 2019-2025 | Dextenza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $217.88 | 2019-2021 | |
| Dompe US, INC. | $187.21 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $187.20 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $176.75 | 2019-2022 | |
| Horizon Therapeutics Plc | $140.87 | 2021-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $140.19 | 2019-2024 | Veritas Vision System, Lipiflow System Activator II (Disposable, Tecnis Iol |
| Rayner Intraocular Lenses Limited | $113.59 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Allergan, INC. | $105.23 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $101.72 | 2022-2025 | Vyzulta, Totalvisc, Envista Envy Iol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $61.15 | 2024-2025 | Xdemvy |
| Amgen INC. | $38.13 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $34.92 | 2023 | Tyrvaya |
| Coherus Oncology, INC. | $30.87 | 2023 | |
| Mallinckrodt Enterprises LLC | $23.89 | 2019 | |
| Biotissue Holdings INC. | $20.75 | 2025 | |
| Lombart Brothers, INC. | $15.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.